XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Thyroid Channel
subscribe to Thyroid newsletter

Latest Research : Cancer : Thyroid

   DISCUSS   |   EMAIL   |   PRINT
Gene Activity can Differentiate Follicular Adenoma from Follicular Thyroid Cancer
Mar 26, 2005, 16:19, Reviewed by: Dr.

“Presently, doctors cannot distinguish between these two conditions without surgical removal of the thyroid, even though only about 10 percent of cases prove to be cancerous.”

 
New research suggests that physicians can distinguish between a type of thyroid cancer and an identical-looking, non-cancerous thyroid condition by simply determining the activity of three genes.

The findings could lead to a test that will prevent the needless loss of the thyroid gland in people with the noncancerous condition.
Charis Eng

The study, led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, indicates that the activity levels of three genes – cyclin D2, PCSK2 (for protein convertase 2) and PLAB (prostate differentiation factor) -- might distinguish the noncancerous condition known as follicular adenoma (FA) from follicular thyroid cancer (FTC).

The findings, published online by the Journal of Clinical Endocrinology and Metabolism, also provide insight into the genetic changes that occur in those cases when FA becomes FTC.

“Presently, doctors cannot distinguish between these two conditions without surgical removal of the thyroid, even though only about 10 percent of cases prove to be cancerous,” says principal investigator Charis Eng, director of OSU’s clinical cancer genetics program. “Follicular adenoma often does not require surgery, and certainly not as extensive as for a cancer.”
“Presently, doctors cannot distinguish between these two conditions without surgical removal of the thyroid, even though only about 10 percent of cases prove to be cancerous.”

“This is the first step in determining whether we can use these three genes as an objective way to tell whether a patient has cancer or simply a benign adenoma before sending that person to surgery,” says Eng, holder of the Klotz Chair in Cancer Research and a recipient of the Doris Duke Distinguished Clinical Scientist Award.

An estimated 25,690 Americans will be diagnosed with thyroid cancer this year, and an estimated 2,370 people will die of the disease. The great majority of thyroid cancers begin as thyroid nodules, which develop in about 7 percent of adult Americans (about 275,000 people in 1999).

To determine if thyroid nodules are cancerous, doctors typically withdraw cells from the nodules using a procedure known as a fine-needle aspiration biopsy. A pathologist then examines the cells to determine if they are noncancerous (benign) or cancerous.

But if the nodules consist of the thyroid’s follicular cells, Eng says, “it is often impossible to tell if they are benign or cancerous.”

So the person is sent to surgery, and the entire thyroid is often removed. Ultimately, however, only 10-20 percent of these cases are actually cancerous. The great majority of patients therefore undergo unnecessary surgery and thyroid loss.

These patients must then take synthetic thyroid-hormone tablets daily for life, with regular testing to adjust the dosage.

For this study, Eng and her colleagues used gene chip technology to compare gene activity levels in nodules from 12 patients with FA and 12 patients with FTC. The comparison included four cases of early (i.e., minimally invasive) FTCs.

Gene-chip analysis compares activity levels of tens of thousands of genes – in this case, 33,000 genes – in a sample at one time.

The researchers focused on the three genes that showed the greatest differences in activity. One gene was almost 145 times more active, a second was eight times more active and the third was 12 times less active in FTC cells compared with FA cells.

The researchers confirmed the gene-chip findings on two additional sets of tissue samples using two other measures of gene activity – a form of polymerase chain reaction (PCR) and immunohistochemistry. The validation tests showed that the three genes could distinguish FTC from FA with an accuracy of 96.7 percent.

Next, the investigators will confirm their findings using fresh thyroid follicular nodule tissue obtained by fine-needle aspiration. This work is under way.
 

- Published online by the Journal of Clinical Endocrinology and Metabolism
 

Journal of Clinical Endocrinology and Metabolism

 
Subscribe to Thyroid Newsletter
E-mail Address:

 

Other OSU researchers involved in this study were Frank Weber, post-doctoral researcher in Eng’s lab; Lei Shen, assistant professor of statistics; Carl D. Morrison, assistant professor of pathology; Matthew D. Ringel, associate professor of internal medicine and co-director of the thyroid cancer unit at the James Cancer Hospital and Solove Research Institute.

Funding from the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute supported this research.


Related Thyroid News

Study demonstrates link between thyroid cancer and the Chornobyl accident
Recombinant TSH therapy promises better quality of life for thyroid cancer patients
A novel molecular diagnostic tool to assess risk for patients with papillary thyroid cancer
Gene Activity can Differentiate Follicular Adenoma from Follicular Thyroid Cancer
Cincinnati study of Chernobyl residents uncovers new cause of thyroid cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us